Orchestra BioMed Stock Forecast
NASDAQ: OBIOHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
OBIO analyst consensus
Consensus (7 analysts)
strong_buy
Avg. price target
$12.43+116.93%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Orchestra BioMed (2026-10-09), 7 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $12.43, with a high estimate of $20.00 and a low estimate of $9.00. The average target implies upside of 116.9% from the current price of $5.73.
The spread between the highest and lowest targets is 122.2%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for OBIO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 14% |
| Buy | 6 | 86% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $9.00 | +57.07% |
| Average target | $12.43 | +116.93% |
| High target | $20.00 | +249.04% |